Zalunfiban at First Medical Contact Improves Outcomes in STEMI Without Major Bleeding Risk: NEJM
Netherlands: Researchers have found in a new study that among patients with ST-elevation myocardial infarction (STEMI), zalunfiban given at the first medical contact significantly improved preintervention infarct-related artery patency and reduced adverse 30-day clinical outcomes. The drug did not increase severe or life-threatening bleeding, though it was linked to more mild to moderate bleeding.
The findings, published in NEJM Evidence, come from an international randomized clinical trial led by Dr. A. W. J. van’t Hof of the Department of Cardiology at University Medical Center Maastricht and his colleagues.
Zalunfiban, a glycoprotein IIb/IIIa inhibitor specifically formulated for rapid subcutaneous administration, has been developed to provide immediate antiplatelet activity in patients suspected of experiencing a STEMI, even before they reach the catheterization laboratory.
In the double-blind, placebo-controlled study, 2,467 patients were randomly assigned in equal proportions to receive either one of two doses of subcutaneous zalunfiban (0.11 mg/kg or 0.13 mg/kg) or a placebo at the earliest point of medical contact. The researchers evaluated the treatment’s impact on a composite hierarchical outcome that ranked seven clinical endpoints—including death, stroke, recurrent myocardial infarction, stent thrombosis, heart failure events, infarct size, or absence of any adverse outcome—over a 30-day follow-up period.
Key Findings:
- Zalunfiban significantly improved the primary multicomponent efficacy endpoint, showing a reduced risk of severe complications in STEMI patients.
- Patients receiving zalunfiban demonstrated better coronary blood flow before intervention, based on angiographic assessments.
- The corrected frame count was faster in the zalunfiban group compared with the placebo group, indicating earlier restoration of perfusion in the infarct-related artery.
- The study did not find an increase in severe or life-threatening bleeding among patients treated with zalunfiban according to GUSTO criteria.
- Rates of severe bleeding were similar between the zalunfiban and placebo groups.
- Mild to moderate bleeding was more common in patients receiving zalunfiban, suggesting a manageable safety consideration for early use of the drug.
Overall, the trial’s conclusions underscore the potential role of zalunfiban as an early-intervention agent capable of enhancing coronary patency and improving short-term clinical outcomes in STEMI care without a major trade-off in severe bleeding risk. The observed increases in milder bleeding episodes appear manageable within the context of acute myocardial infarction treatment, where rapid restoration of blood flow is critical.
"These results provide compelling evidence supporting the incorporation of zalunfiban into prehospital STEMI management strategies. Further studies may help refine dosing, evaluate long-term outcomes, and determine how this early therapeutic approach integrates into existing reperfusion protocols.
Reference:
DOI: 10.1056/EVIDoa2500268
Next Story